Pfizer (NYSE:PFE) reported Q2 EPS of $2.04, $0.33 better than the analyst estimate of $1.71. Revenue for the quarter came in at $27.7 billion versus the consensus estimate of $25.26 billion.
GUIDANCE:
Pfizer sees FY2022 EPS of $6.30-$6.45, versus the consensus of $6.62. Pfizer sees FY2022 revenue of $98-102 billion, versus the consensus of $103 billion.
Reaffirms 2022 Revenue Guidance for Comirnaty(1) and Paxlovid of ~$32 Billion and ~$22 Billion, Respectively, Despite Unfavorable Impacts from Foreign Exchange